Third's A Charm? Merck Again Faces FDA Panel To Request Mevacor Switch To OTC
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA’s Nonprescription Drugs and Endocrinologic and Metabolic Drugs committees to review Mevacor Rx-to-OTC switch proposal Dec. 13.
You may also be interested in...
GlaxoSmithKline To Market Merck’s Mevacor OTC In U.S.
An FDA joint advisory committee meets Dec. 13 to evaluate Merck data supporting the Rx-to-OTC switch.
GlaxoSmithKline To Market Merck’s Mevacor OTC In U.S.
An FDA joint advisory committee meets Dec. 13 to evaluate Merck data supporting the Rx-to-OTC switch.
Merck Regroups On Mevacor Switch; Will CUSTOM Analysis Pave The Way?
J&J/Merck joint venture is working to solve self-selection issues that led to an FDA “not approvable” decision on the OTC switch application for the statin in 2005.